199 related articles for article (PubMed ID: 11385711)
1. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
Vega A; Campos B; Bressac-De-Paillerets B; Bond PM; Janin N; Douglas FS; Domènech M; Baena M; Pericay C; Alonso C; Carracedo A; Baiget M; Diez O
Hum Mutat; 2001 Jun; 17(6):520-1. PubMed ID: 11385711
[TBL] [Abstract][Full Text] [Related]
2. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
3. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
4. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
5. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
6. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin.
Santos C; Peixoto A; Rocha P; Vega A; Soares MJ; Cerveira N; Bizarro S; Pinheiro M; Pereira D; Rodrigues H; Castro F; Henrique R; Teixeira MR
Fam Cancer; 2009; 8(3):203-8. PubMed ID: 19123044
[TBL] [Abstract][Full Text] [Related]
7. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
[TBL] [Abstract][Full Text] [Related]
8. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
10. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
[TBL] [Abstract][Full Text] [Related]
11. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
Russo A; Calò V; Bruno L; Schirò V; Agnese V; Cascio S; Foddai E; Fanale D; Rizzo S; Di Gaudio F; Gulotta E; Surmacz E; Di Fede G; Bazan V
Breast Cancer Res Treat; 2009 Jan; 113(1):67-70. PubMed ID: 18228134
[TBL] [Abstract][Full Text] [Related]
12. Independent origin of 185delAG BRCA1 mutation in an Indian family.
Kadalmani K; Deepa S; Bagavathi S; Anishetty S; Thangaraj K; Gajalakshmi P
Neoplasma; 2007; 54(1):51-6. PubMed ID: 17203892
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
Zhang L; Chen L; Bacares R; Ruggeri JM; Somar J; Kemel Y; Stadler ZK; Offit K
Breast Cancer Res Treat; 2011 Dec; 130(3):1051-6. PubMed ID: 21863257
[TBL] [Abstract][Full Text] [Related]
14. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
16. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Yang Y; Swaminathan S; Martin BK; Sharan SK
Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
18. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
19. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
Millevoi S; Bernat S; Telly D; Fouque F; Gladieff L; Favre G; Vagner S; Toulas C
Breast Cancer Res Treat; 2010 Apr; 120(2):391-9. PubMed ID: 19404736
[TBL] [Abstract][Full Text] [Related]
20. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
